Program
Levonorgestrel
Also written as “Levonorgestrel/Ethinyl Estradiol”, “levonorgestrel” and “ethinyl estradiol and levonorgestrel; exenatide”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Menorrhagia · Premenstrual Syndrome · Endometriosis · Endometrial Hyperplasia, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 180 open or running | phase 4since Oct 26, 2006 | Sep 13, 2005 | none ahead |
| Pfizer | 90 open or running | phase 3since Aug 8, 2005 | Aug 8, 2005 | none ahead |
| Teva Pharmaceutical Industries | 50 open or running | phase 3since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Grünenthal | 30 open or running | phase 1since Nov 12, 2019 | Nov 12, 2019 | none ahead |
| Agile Therapeutics | 20 open or running | phase 2since Nov 29, 2010 | Nov 29, 2010 | none ahead |
| chemo-research | 11 open or running | phase 3since Jul 20, 2026 | Jul 20, 2026 | Dec 2030phase 3 · NCT07734155 |
| corium-innovations-inc | 11 open or running | phase 1since Aug 26, 2026 | Aug 26, 2026 | May 31, 2027phase 1 · NCT07794150 |
| nextfertility | 11 open or running | no phasesince Feb 26, 2024 | Feb 26, 2024 | none ahead |
Also a collaborator on its studies: Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 26 studies since Aug 8, 2005.
- Jun 18, 2012Phase 2 study in HealthyAgile Therapeutics · NCT01623466 · 36 enrolled
- Jul 28, 2014Phase 2 study in EndometriosisBayer · NCT02203331 · 319 enrolled · United States, Austria, Belgium and more
- Mar 26, 2015Phase 3 study in ContraceptionBayer · NCT02403401 · 1,471 enrolled · United States, Japan
- Sep 8, 2015Phase 1 study in EndometriosisBayer · NCT02545452 · 52 enrolled · Germany
- Dec 5, 2016Phase 3 study in MenorrhagiaBayer · NCT02985541 · 364 enrolled · United States
- Mar 3, 2017Phase 3 study in ContraceptionBayer · NCT03074045 · 145 enrolled · Russian Federation
- Sep 5, 2018Phase 1 study in Healthy FemalesPfizer · NCT03662516 · 17 enrolled · United States
- Nov 12, 2019Grünenthal's first study: phase 1 study in BioequivalenceNew to GrünenthalGrünenthal · NCT04194905 · 10 enrolled · Chile
- Jan 13, 2020Phase 1 study in BioequivalenceGrünenthal · NCT04230070 · 30 enrolled · Chile
- Feb 25, 2022Phase 1 study in Therapeutic EquivalencyGrünenthal · NCT05282940 · 36 enrolled · India
- Feb 26, 2024nextfertility's first study: no phase study in Infertility, FemaleNew to nextfertilitynextfertility · NCT06304220 · 210 planned · Spain
- Mar 21, 2025Phase 3 study in Endometrial HyperplasiaBayer · NCT06904274 · United States, Canada, China
- Jul 20, 2026chemo-research's first study: phase 3 study in Contraception BehaviorNew to chemo-researchchemo-research · NCT07734155 · 1,600 planned
- Aug 26, 2026corium-innovations-inc's first study: phase 1 study in MenopauseNew to corium-innovations-inccorium-innovations-inc · NCT07794150 · 250 planned · United States, India
Ahead
- May 31, 2027Primary completion: phase 1 study in Menopausecorium-innovations-inc · NCT07794150
- Dec 2030Primary completion: phase 3 study in Contraception Behaviorchemo-research · NCT07734155
TargetBeta
“Progesterone receptor agonist”ChEMBL 37, by rule
Other programs on PGR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| drospirenonerule | estetra | phase 4 | 20 |
| Megestrol Acetaterule | Changchun GeneScience Pharmaceutical | phase 4 | 19 |
| Medroxyprogesterone Acetaterule | Pfizer | phase 4 | 11 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Utrogestanrule | calla-lily-clinical-care-ltd | phase 1 | 1 |
Studies
All 40 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07794150Menopause · United States, India | 1 | Recruiting | corium-innovations-inc | May 31, 2027 | 250 |
| NCT07734155Contraception Behavior | 3 | Not yet recruiting | chemo-research | Dec 2030 | 1,600 |
| NCT06904274Endometrial Hyperplasia · United States, Canada, China | 3 | Withdrawn | Bayer | Jun 17, 2026 | 0 |
| NCT06304220Infertility, Female · Spain | – | Not yet recruiting | nextfertility | Sep 2024 | 210 |
| NCT05282940Therapeutic Equivalency · India | 1 | Completed | Grünenthal | Mar 15, 2022 | 36 |
| NCT04230070Bioequivalence · Chile | 1 | Completed | Grünenthal | Oct 31, 2020 | 30 |
| NCT04194905Bioequivalence · Chile | 1 | Completed | Grünenthal | Nov 21, 2020 | 10 |
| NCT03662516Healthy Females · United States | 1 | Completed | Pfizer | Jan 19, 2019 | 17 |
| NCT03074045Contraception · Russian Federation | 3 | Completed | Bayer | Sep 3, 2018 | 145 |
| NCT02985541Menorrhagia · United States | 3 | Completed | Bayer | May 28, 2021 | 364 |
| NCT02545452Endometriosis · Germany | 1 | Completed | Bayer | Mar 14, 2016 | 52 |
| NCT02403401Contraception · United States, Japan | 3 | Completed | Bayer | Jul 7, 2016 | 1,471 |
| NCT02203331Endometriosis · United States, Austria, Belgium and more | 2 | Completed | Bayer | Oct 24, 2016 | 319 |
| NCT01623466Healthy | 2 | Completed | Agile Therapeutics | Sep 2012 | 36 |
| NCT01434160Contraception · Austria, Belgium, Denmark and more | 3 | Completed | Bayer | Jun 2013 | 304 |
| NCT01397097Contraception · Australia, Finland, France and more | 3 | Completed | Bayer | Jun 2013 | 766 |
| NCT01250210Ovulation Suppression · United States | 2 | Completed | Agile Therapeutics | Feb 2008 | 123 |
| NCT01254292Contraception · United States, Austria, Belgium and more | 3 | Completed | Bayer | Jan 8, 2013 | 567 |
| NCT01096498Contraception · Mexico | 1 | Completed | Bayer | Mar 2009 | 24 |
| NCT01096485Contraception · Mexico | 1 | Completed | Bayer | Mar 2009 | 24 |
| NCT01073904Contraceptives, Postcoital · Mexico | 1 | Completed | Bayer | Sep 2009 | 32 |
| NCT00996580Pregnancy Prevention · United States | 3 | Completed | Teva Pharmaceutical Industries | Sep 2011 | 3,597 |
| NCT00924560Bone Mineral Density · United States | 2 | Completed | Teva Pharmaceutical Industries | Aug 2012 | 1,361 |
| NCT00884260Contraception · Australia, China, Korea, Republic of | 3 | Completed | Bayer | Jun 2013 | 918 |
| NCT00777556Emergency Contraception · United States | 3 | Completed | Teva Pharmaceutical Industries | Dec 2010 | 343 |
| NCT00696202Medicated Intrauterine Devices · France | 4 | Completed | Bayer | 199 | |
| NCT00498784Contraception · France | 4 | Completed | Bayer | Oct 2007 | 141 |
| NCT00447863Contraception | 1 | Withdrawn | Pfizer | 0 | |
| NCT00394771Metrorrhagia · United States | 2 | Completed | Teva Pharmaceutical Industries | Mar 2008 | 567 |
| NCT00393198Menorrhagia · Finland, France, Ireland and more | 4 | Completed | Bayer | Oct 2012 | 204 |
| NCT00360490Menorrhagia · United States, Argentina, Brazil and more | 3 | Completed | Bayer | Jun 2008 | 165 |
| NCT00319163Healthy · United States | 1 | Completed | Pfizer | Nov 2006 | 26 |
| NCT00254189Ovulation | 2 | Completed | Pfizer | 60 | |
| NCT00248963Oral Contraceptive | 3 | Completed | Pfizer | 600 | |
| NCT00245921Contraception | 3 | Completed | Pfizer | Oct 2005 | 2,000 |
| NCT00195559Premenstrual Syndrome · Argentina, Brazil, Chile and more | 3 | Completed | Pfizer | 526 | |
| NCT00185380Contraception · Finland, Hungary, Norway and more | 2 | Completed | Bayer | Dec 2008 | 742 |
| NCT00196326Contraception · United States | 3 | Completed | Teva Pharmaceutical Industries | Jun 2007 | 2,235 |
| NCT00161681Premenstrual Syndrome · United States | 3 | Completed | Pfizer | Aug 2006 | 200 |
| NCT00128934Menstruation Disturbances · United States, Canada | 3 | Completed | Pfizer | 744 |
How it is read
Names in the registry
- “Levonorgestrel/Ethinyl Estradiol”, 5 entries
- “levonorgestrel”, 5 entries
- “Levonorgestrel”, 3 entries
- “ethinyl estradiol and levonorgestrel; exenatide”, 3 entries
- “Ethinyl Estradiol + Levonorgestrel”, 2 entries
Codes read as this program: BAY865028.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 3 studies
- Menorrhagia, 3 studies
- Premenstrual Syndrome, 3 studies
- Endometriosis, 2 studies
- Endometrial Hyperplasia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.